In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Here’s the skinny on chubby baby boys. Most folks find chunky newborns plum adorable, owing to their squeezable cheeks, plump ...
Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...
The androgen clock is rewriting the science of aging, offering a precise way to measure hormone exposure and its profound effects on health, longevity, and biology.
RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback